ABL1 and neoplasm: While BCR-ABL-based subclassification and associated target therapy remain the standard care for CML patients, there is growing evidence showing that a minority of mutational subclones within CML are highly resistant to tyrosine kinase inhibitors,22, 23, 24 suggesting that subclassification based on intertumor heterogeneity may not capture the full tumor spectrum.